Get the Stockscreener App
2.05
10.87%
-0.25
After Hours:
2.08
0.03
+1.46%
Rein Therapeutics Inc stock is traded at $2.05, with a volume of 125.36K.
It is down -10.87% in the last 24 hours and up +0.00% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
See More
Previous Close:
$2.30
Open:
$2.18
24h Volume:
125.36K
Relative Volume:
4.32
Market Cap:
$43.33M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.06%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.00
$2.295
1-Week Range:
$1.88
$2.41
52-Week Range:
$1.8396
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
2.05 | 43.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Smart brands rein in ad spending when a rival faces a setback − here’s why - Yahoo Finance
Zimbabwe Plans New Measures to Rein In Proliferating Informal Sector - Yahoo Finance
United Therapeutics president sells shares worth $3.7 million - MSN
Rodman & Renshaw sets $8 target for Rein Therapeutics stock By Investing.com - Investing.com Canada
Analysis-Trump's digital dollar ban gives China and Europe's CBDCs free rein - Yahoo Finance
Rodman & Renshaw sets $8 target for Rein Therapeutics stock - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Stock market news: Blackboxstocks +105.33%, ScanTech AI Systems +59.14% among top gainers during mid day trading - Business Upturn
Aileron Therapeutics, Inc. announced that it has received $42 million in funding from a group of investors. - Marketscreener.com
Atara stock extends losses on FDA clinical hold (ATRA:NASDAQ) - Seeking Alpha
GeneTether Therapeutics Rebrands as Rize Oncology, Focuses on Cancer Treatment - MSN
Old Lyme horse riding center gives Parkinson's patients the reins - theday.com
Free Rein Coffee Company® Expands Distribution of Free Rein Reserve™ Collection - Yahoo Canada Finance
Aileron straps in for 2025 with a new name: Rein Therapeutics - FiercePharma
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes -April 01, 2019 at 06:16 am EDT - Marketscreener.com
Aileron Therapeutics to be Included in the Russell Microcap® Index - Marketscreener.com
Aileron Therapeutics Announces Appointments to Scientific Advisory Board -March 28, 2018 at 07:00 am EDT - Marketscreener.com
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer - Marketscreener.com
Aileron Therapeutics Announces Board Appointments -June 24, 2019 at 08:00 am EDT - Marketscreener.com
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Marketscreener.com
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Marketscreener.com
Aileron Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces CEO Changes -March 12, 2024 at 08:00 am EDT - Marketscreener.com
Aileron Therapeutics Announces Management Changes -September 06, 2018 at 09:10 am EDT - Marketscreener.com
Rein Therapeutics announces name change and new ticker By Investing.com - Investing.com South Africa
Rein Therapeutics announces name change and new ticker - Investing.com
Aileron Therapeutics announces rebranding to Rein Therapeutics - MSN
Aileron Therapeutics Announces Rebranding to Rein Therapeutics - PR Newswire
Aileron Rebrands as Rein Therapeutics Following Breakthrough IPF Drug Trial Success - StockTitan
Warren Stephens steps down, turns reins of Stephens, Inc. over to his sons - KARK
New law set to rein in drug costs for many in Mass. - GazetteNET
Achilles Therapeutics sells technology assets to AstraZeneca - Seeking Alpha
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
Reins of Life in South Bend rides ahead with major expansion - WSBT-TV
Empyrean Technology gives control to CEC after U.S. blacklisting — China’s top developer of chip design systems hands reins to state-owned firm - Yahoo Finance
Saudi Arabia to rein in spending next year - Yahoo! Voices
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs - Yahoo Finance
Cogent Biosciences to Present Key Bezuclastinib Trial Data at ASH 2024 Meeting - StockTitan
Starbucks needs you to rein in highly customized drink orders — ‘We have some cleanup to do,’ CEO Brian Niccol says - Yahoo Finance
Chester County nonprofit provides therapeutic services while on horseback - 6ABC Philadelphia
Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha
AI takes the reins: consumers embrace artificial intelligence for holiday shopping, Talkdesk 2024 Holiday Survey reveals - Yahoo Finance
It's time to rein in sports betting - Yahoo Finance
Cole Hauser's Free Rein Coffee Company Announces Its First National Retail Expansion with Walmart, Serving Those Who Serve™ Their Country and Communities Nationwide - Yahoo Finance
Reins Of LifeTherapeutic Horseback Riding - WSBT-TV
Flowcode Partners with REIN to Bring AI to the Insurance Industry - Yahoo Finance
Tonix stock jumps on collaboration for mpox vaccine candidate (NASDAQ:TNXP) - Seeking Alpha
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rein Therapeutics Inc Stock (RNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 17 '24 |
Sale |
3.25 |
4,707 |
15,298 |
1,746,549 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 14 '24 |
Sale |
3.30 |
1,900 |
6,270 |
1,751,256 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 10 '24 |
Sale |
3.30 |
9,577 |
31,604 |
1,768,250 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 12 '24 |
Sale |
3.25 |
9,342 |
30,362 |
1,753,156 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 11 '24 |
Sale |
3.26 |
5,752 |
18,744 |
1,762,498 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 05 '24 |
Sale |
3.30 |
6,291 |
20,760 |
1,783,851 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 06 '24 |
Sale |
3.29 |
4,284 |
14,104 |
1,779,567 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 07 '24 |
Sale |
3.26 |
1,740 |
5,664 |
1,777,827 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
May 01 '24 |
Sale |
4.21 |
20,315 |
85,473 |
1,779,306 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Apr 29 '24 |
Sale |
4.95 |
10,746 |
53,182 |
1,799,711 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):